

## Key Figures of Consolidated Financial Results for 3rd Quarter FY2024

February 3rd, 2025  
Sumitomo Chemical Co., Ltd.  
(Billions of yen)

### 1. Financial Summary (IFRS)

	Q3 FY2024	Q3 FY2023	Variance	FY2024 (Forecast)	FY2023	Variance
Sales revenue	1,904.8	1,806.9	98.0	2,600.0	2,446.9	153.1
Core operating income (loss)	60.1	(113.9)	173.9	100.0	(149.0)	249.0
Operating income (loss)	145.4	(160.6)	306.1	180.0	(488.8)	668.8
Net income (loss) attributable to owners of the parent	28.6	(109.8)	138.4	25.0	(311.8)	336.8
Basic earnings (loss) per share	¥ 17.47	¥ (67.13)	¥ 84.60	¥ 15.28	¥ (190.69)	¥ 205.97
Return on equity	3.0%	(9.4)%	12.4%	2.6%	(29.2)%	31.8%
Overseas sales revenue	69.8%	68.2%	1.6%	70.0%	68.0%	2.0%
Exchange rate (yen/\$)	152.64	143.33	—	151.98 (Jan.-Mar. 150.00)	144.59	—
Naphtha price (yen/kl)	76,500	68,000	—	75,000 (Jan.-Mar. 70,000)	69,100	—

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

### 2. Sales Revenue / Core Operating Income by Business Segment (IFRS)

(Billions of yen)

		Q3 FY2024	Q3 FY2023	Variance	FY2024 (Forecast)	FY2023	Variance
Agro & Life Solutions	Sales revenue	363.1	347.2	15.9	550.0	515.6	34.4
	Core operating income	19.5	(2.9)	22.4	53.0	26.4	26.6
ICT & Mobility Solutions	Sales revenue	461.2	441.3	19.9	600.0	587.4	12.6
	Core operating income	59.7	44.0	15.8	65.0	50.0	15.0
Advanced Medical Solutions	Sales revenue	40.7	38.2	2.5	70.0	58.5	11.5
	Core operating income	1.2	3.0	(1.8)	3.0	6.1	(3.1)
Essential & Green Materials	Sales revenue	672.9	681.7	(8.8)	910.0	885.9	24.1
	Core operating income	(44.3)	(60.5)	16.2	(64.0)	(89.1)	25.1
Sumitomo Pharma	Sales revenue	292.8	234.7	58.1	380.0	313.8	66.2
	Core operating income	19.9	(96.4)	116.2	24.0	(126.4)	150.4
Others	Sales revenue	74.1	63.8	10.3	90.0	85.8	4.2
	Core operating income	23.8	12.1	11.6	60.0	11.6	48.4
Adjustments	Sales revenue	—	—	—	—	—	—
	Core operating income	(19.6)	(13.1)	(6.5)	(41.0)	(27.7)	(13.3)
Total	Sales revenue	1,904.8	1,806.9	98.0	2,600.0	2,446.9	153.1
	Core operating income	60.1	(113.9)	173.9	100.0	(149.0)	249.0

\*The Group changed its reportable segments from Q3 FY2024. The segment information for Q3 FY2023, FY2023, and the forecast for FY2024 have been reclassified to reflect the change in the reportable segments. Please refer to page 12 for details.

\*The reclassification of segment information for FY2023 and the forecast for FY2024 are based on estimates, as a part of a consolidated subsidiary is planning to change its segments in Q4 FY2024.

### 3. Summary of Consolidated Statement of Income (IFRS)

(Billions of yen)

	Q3 FY2024	Q3 FY2023	Variance	Variance Ratio
Sales revenue	1,904.8	1,806.9	98.0	5.4%
Core operating income (loss)	60.1	(113.9)	173.9	—
Of which equity in earnings	(53.3)	(35.2)	(18.1)	—
Total non-recurring items	85.4	(46.8)	132.1	—
Of which share of profit (loss) of investments accounted for using the equity method (non-recurring factors)	86.0	(5.1)	91.0	—
Of which gains on sales of property, plant and equipment, and intangible assets	11.5	1.1	10.3	—
Of which gains on fair value measurement of the residual interest	9.4	—	9.4	—
Of which restructuring costs	(14.8)	(25.6)	10.8	—
Of which impairment losses	(5.5)	(15.4)	9.9	—
Others	(1.2)	(1.8)	0.6	—
Operating income (loss)	145.4	(160.6)	306.1	—
Finance income/expenses	(105.4)	0.7	(106.0)	—
Of which gain (loss) on foreign currency transactions including gain (loss) on derivatives	15.0	6.1	9.0	—
Of which loss on debt waiver for a loan	(109.8)	—	(109.8)	—
Income (loss) before taxes	40.1	(160.0)	200.0	—
Income tax expenses	0.6	(5.0)	5.6	—
Net income (loss)	40.7	(164.9)	205.6	—
Net (income) loss attributable to non-controlling interests	(12.1)	55.2	(67.3)	—
Net income (loss) attributable to owners of the parent	28.6	(109.8)	138.4	—
ROE	3.0%	(9.4)%		
Exchange rate (yen/\$)	152.64	143.33		
Naphtha price (yen/kl)	76,500	68,000		
Overseas sales revenue ratio	69.8%	68.2%		

### 4. Summary of Consolidated Statement of Financial Position (IFRS)

(Billions of yen)

	31-Dec-24	31-Mar-24	Variance		31-Dec-24	31-Mar-24	Variance
Current Assets	1,725.7	1,675.9	49.8	Liabilities	2,586.7	2,770.5	(183.7)
Cash and cash equivalents	258.3	217.4	40.9	Trade and other payables	525.7	543.4	(17.7)
Trade and other receivables	568.9	620.0	(51.1)	Interest-bearing liabilities	1,443.7	1,563.5	(119.8)
Inventories	708.5	709.6	(1.1)	Others	617.4	663.6	(46.2)
Others	190.0	128.8	61.2	Equity	1,152.8	1,164.4	(11.6)
Non-current assets	2,013.8	2,258.9	(245.2)	Shareholders' equity	717.0	660.0	57.0
Property, plant and equipment	796.7	796.5	0.1	Other components of equity	230.9	305.8	(74.9)
Goodwill and intangible assets	534.3	536.7	(2.4)	Non-controlling interests	204.9	198.6	6.3
Others	682.9	925.7	(242.9)				
Total	3,739.5	3,934.8	(195.3)	Total	3,739.5	3,934.8	(195.3)
				Ratio of equity attributable to owners of the parent to total assets	25.3%	24.5%	0.8%
				D/E ratio (times)	1.3	1.3	(0.1)

## 5. Summary of Consolidated Statement of Cash Flows (IFRS)

(Billions of yen)

	Q3 FY2024	Q3 FY2023	Variance	FY2023
Cash flows from operating activities	140.7	(135.0)	275.7	(51.3)
Cash flows from investing activities	56.7	(77.8)	134.5	(112.2)
Free cash flows	197.5	(212.8)	410.2	(163.6)
Cash flows from financing activities	(141.7)	161.1	(302.8)	49.2
Others	(2.5)	20.8	(23.4)	28.7
Increase (decrease) in cash and cash equivalents	53.2	(30.8)	84.1	(85.6)
Cash and cash equivalents at the end of the period	258.3	276.2	(17.9)	217.4

Note: This document has been translated from the Japanese-language original (hereinafter, the "original") for reference purposes only. In the event of any discrepancy between this translated document and the original, the original shall prevail. The original of Quarterly Consolidated Financial Statements has undergone a review by the Company's audit firm. Please refer to the Japanese review report for details.



February 3, 2025

## Summary of Consolidated Financial Results for Third Quarter Fiscal Year 2024 (Under IFRS)

Company name: Sumitomo Chemical Co., Ltd.  
 Listing: Tokyo Stock Exchange  
 Securities code: 4005  
 URL: <https://www.sumitomo-chem.co.jp/english/>  
 Representative: Keiichi Iwata, Representative Director & President  
 Inquiries: Shunji Kobayashi, General Manager, Corporate Communications Dept.  
 Telephone: +81-3-5201-0200  
 Scheduled date to commence dividend payments: —  
 Preparation of supplementary material on financial results: Yes  
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(All amounts are rounded to the nearest million yen.)

### 1. Consolidated Financial Results for Third Quarter Fiscal Year 2024 (April 1, 2024 to December 31, 2024)

#### (1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Sales revenue		Core operating income		Operating income		Net income		Net income attributable to owners of the parent		Total comprehensive income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Q3 FY2024	1,904,833	5.4	60,065	—	145,434	—	40,694	—	28,581	—	977	—
Q3 FY2023	1,806,869	(19.9)	(113,866)	—	(160,634)	—	(164,946)	—	(109,778)	—	(13,058)	—

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Q3 FY2024	17.47	17.47
Q3 FY2023	(67.13)	—

Reference: Share of profit or loss of investments accounted for using the equity method

Q3 FY2024: ¥ 32,644 million      Q3 FY2023: ¥ (40,277) million

Income before taxes

Q3 FY2024: ¥ 40,071 million      Q3 FY2023: ¥ (159,953) million

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

\*For diluted earnings per share for Q3 FY2023, although there are potential shares, they are not listed because they have an anti-dilutive effect.

#### (2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
December 31, 2024	3,739,477	1,152,767	947,894	25.3
March 31, 2024	3,934,818	1,164,366	965,753	24.5

## 2. Dividends

	Dividends per share				
	1st quarter end	2nd quarter end	3rd quarter end	Year-end	Annual
FY2023	Yen —	Yen 6.00	Yen —	Yen 3.00	Yen 9.00
FY2024	—	3.00	—		
FY2024 (Forecast)				6.00	9.00

Note: Revision of dividend forecasts from the latest announcement: None

## 3. Consolidated Financial Forecasts for Fiscal Year 2024 (April 1, 2024 to March 31, 2025)

(Percentages indicate year-on-year changes.)

	Sales revenue		Core operating income		Operating income		Net income attributable to owners of the parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full-year of FY2024	2,600,000	6.3	100,000	—	180,000	—	25,000	—	15.28

Note: Revision of financial forecasts from the latest announcement: None

### Notes:

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: —

Excluded: 1 company (Sumitomo Bakelite Co., Ltd.)

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: Yes

(3) Number of shares issued (common shares)

(i) Total number of shares issued at the end of the period (including treasury shares)

As of December 31, 2024	1,657,217,608 shares
As of March 31, 2024	1,656,449,145 shares

(ii) Number of treasury shares at the end of the period

As of December 31, 2024	20,512,972 shares
As of March 31, 2024	20,500,922 shares

(iii) Average number of shares outstanding during the period

Nine Months ended December 31, 2024	1,635,875,454 shares
Nine Months ended December 31, 2023	1,635,316,629 shares

\* Review of the Japanese-language original of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: Yes (voluntary)

\* Notes to appropriate use of forecasts and other special items:

Descriptions regarding forward-looking statements about the future performance of the Company contained in this summary are based on information currently available to the Company and certain assumptions judged reasonable and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; rise in prices of raw materials; and fluctuations in foreign exchange rates.

## Attachments

1. Summary of Operating Results for Third Quarter Fiscal Year 2024 .....	2
(1) Operating Results .....	2
(2) Consolidated Financial Position .....	3
(3) Consolidated Forecast and Other Forward-Looking Information .....	3
2. Consolidated Financial Statements and Major Notes .....	4
(1) Consolidated Statement of Financial Position .....	4
(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income .....	6
(3) Consolidated Statement of Changes in Equity .....	8
(4) Consolidated Statement of Cash Flows .....	10
(5) Notes to Consolidated Financial Statements .....	11
(Framework of Financial Report) .....	11
(Going Concern Assumption) .....	11
(Changes in Accounting Estimates) .....	11
(Segment Information) .....	12

## 1. Summary of Operating Results for Third Quarter Fiscal Year 2024

### (1) Operating Results

For Q3 FY2024, the Group's sales revenue increased by ¥98.0 billion compared to Q3 FY2023, to ¥1,904.8 billion. In terms of profits and losses, core operating income\* was ¥60.1 billion. Operating income was ¥145.4 billion owing to a share of profit of investments accounted for using the equity method in Rabigh Refining and Petrochemical Company (hereinafter, "Petro Rabigh") due to debt forgiveness. Net income attributable to owners of the parent was ¥28.6 billion as a result of recording a loss on the waiver of the shareholder loans to Petro Rabigh. Results in every category of income improved compared to Q3 FY2023.

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

The Group changed reportable segments in accordance with the reorganization implemented on October 1, 2024. Please refer to "2. (5) Notes to Consolidated Financial Statements, Segment Information" for details.

The financial results by business segment for Q3 FY2024 are as follows:

#### Agro & Life Solutions

While there was a deterioration in market conditions for crop protection products in the Americas, shipments remained strong in locations such as India. Moreover, market conditions for methionine (feed additives) improved compared to Q3 FY2023. As a result, sales revenue increased by ¥15.9 billion from Q3 FY2023 to ¥363.1 billion. Core operating income was ¥19.5 billion, improved by ¥22.4 billion from Q3 FY2023.

#### ICT & Mobility Solutions

Shipments of display-related materials and processing materials for semiconductors, such as high-purity chemicals and photoresists, increased because of higher demand. As a result, sales revenue increased by ¥19.9 billion from Q3 FY2023, to ¥461.2 billion. Core operating income ¥59.7 billion, increased by ¥15.8 billion from Q3 FY2023.

#### Advanced Medical Solutions

Shipments of active pharmaceutical ingredients and intermediates remained strong. As a result, sales revenue was ¥40.7 billion, about the same level as Q3 FY2023. Core operating income was ¥1.2 billion, decreased by ¥1.8 billion from Q3 FY2023, due to an increase in fixed costs.

#### Essential & Green Materials

Selling prices for synthetic resins, methyl methacrylate and various industrial chemicals increased due to higher raw material prices. On the other hand, shipments of aluminum decreased due to the Group's exit from the business. As a result, sales revenue decreased by ¥8.8 billion from Q3 FY2023, to ¥672.9 billion. Core operating income posted a loss of ¥44.3 billion, improved by ¥16.2 billion from Q3 FY2023, due to an improvement in market conditions, while there was a deterioration in the financial performance of Petro Rabigh, an affiliated company accounted for by the equity-method.

#### Sumitomo Pharma

In North America, there was an increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer), MYFEMBREE® (therapeutic agent for uterine fibroids and endometriosis) and GEMTESA® (therapeutic agent for overactive bladder). On the other hand, in Japan, sales revenue was affected by National Health Insurance (NHI) drug price revisions. As a result, sales revenue increased by ¥58.1 billion from Q3 FY2023, to ¥292.8 billion. Core operating income was ¥19.9 billion, improved by ¥116.2 billion from Q3 FY2023, because of increased sales revenue and significant reduction in selling, general and administrative expenses including research and development expenses, primarily resulting from the effects of business structure improvement through the restructuring of the Group companies in North America and the selection and concentration of research and development investments. Sales revenue and core operating income differ between this segment and Sumitomo Pharma, Co., Ltd., a subsidiary of Sumitomo Chemical Co., Ltd. (hereinafter, the "Company"), due to the Group's contract development and manufacturing organization business for regenerative medicine and cell therapy products not being included in this segment and the Group's consolidated account processing.

## Others

In addition to the above five segments, the Group supplies radiopharmaceuticals, electric power and steam, designs chemical plants and supervises the construction of those facilities, as well as provides transportation and warehousing. Sales revenue of these businesses increased by ¥10.3 billion from Q3 FY2023, to ¥74.1 billion. Core operating income increased by ¥11.6 billion from Q3 FY2023, to ¥23.8 billion, due to a transfer of shares in Sumitomo Bakelite Co., Ltd. which was an affiliated company accounted for by the equity-method.

## (2) Consolidated Financial Position

As of the end of Q3 FY2024, total assets decreased by ¥195.3 billion compared to the end of FY2023, to ¥3,739.5 billion. Other financial assets decreased mainly due to transfers of shares.

Total liabilities decreased by ¥183.7 billion compared to the end of FY2023, to ¥2,586.7 billion. Interest-bearing liabilities decreased by ¥119.8 billion compared to the end of FY2023, to ¥1,443.7 billion.

Total equity (including non-controlling interests) was essentially unchanged from the end of FY2023, with ¥1,152.8 billion. The ratio of equity attributable to the owners of the parent increased by 0.8 percentage points compared to the end of FY2023, to 25.3%.

## (3) Consolidated Forecast and Other Forward-Looking Information

There is no change from the consolidated financial forecasts announced on October 30, 2024.

Financial Forecast by changed Segment for the Full Year Ending March 31, 2025

(Millions of yen)

		FY2024 Forecast
Agro & Life Solutions	Sales revenue	550,000
	Core operating income	53,000
ICT & Mobility Solutions	Sales revenue	600,000
	Core operating income	65,000
Advanced Medical Solutions	Sales revenue	70,000
	Core operating income	3,000
Essential & Green Materials	Sales revenue	910,000
	Core operating income	(64,000)
Sumitomo Pharma	Sales revenue	380,000
	Core operating income	24,000
Others & Adjustments	Sales revenue	90,000
	Core operating income	19,000
Total	Sales revenue	2,600,000
	Core operating income	100,000

## 2. Consolidated Financial Statements and Major Notes

### (1) Consolidated Statement of Financial Position

Millions of yen	As of December 31, 2024	As of March 31, 2024
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	¥ 258,301	¥ 217,449
Trade and other receivables	568,873	620,022
Other financial assets	47,353	31,338
Inventories	708,545	709,637
Other current assets	71,017	79,077
Subtotal	1,654,089	1,657,523
Assets held for sale	71,623	18,359
Total current assets	1,725,712	1,675,882
Non-current assets:		
Property, plant and equipment	796,654	796,526
Goodwill	271,328	263,757
Intangible assets	262,930	272,921
Investments accounted for using the equity method	282,582	319,988
Other financial assets	219,280	412,747
Retirement benefit assets	105,086	110,390
Deferred tax assets	40,563	37,070
Other non-current assets	35,342	45,537
Total non-current assets	2,013,765	2,258,936
Total assets	¥ 3,739,477	¥ 3,934,818

**Liabilities and equity****Liabilities**

## Current liabilities:

Bonds and borrowings	¥	539,603	¥	585,905
Trade and other payables		525,651		543,384
Other financial liabilities		85,269		77,610
Income taxes payable		28,114		8,545
Provisions		102,122		90,919
Other current liabilities		98,188		129,087
Subtotal		1,378,947		1,435,450
Liabilities directly associated with assets held for sale		16,633		8,037
Total current liabilities		1,395,580		1,443,487
Non-current liabilities:				
Bonds and borrowings		904,100		977,581
Other financial liabilities		96,132		100,144
Retirement benefit liabilities		28,089		30,589
Provisions		25,958		46,059
Deferred tax liabilities		99,245		121,146
Other non-current liabilities		37,606		51,446
Total non-current liabilities		1,191,130		1,326,965
Total liabilities		2,586,710		2,770,452

**Equity**

Share capital		90,059		89,938
Capital surplus		51		237
Retained earnings		635,283		578,175
Treasury shares		(8,359)		(8,355)
Other components of equity		225,047		304,033
Other comprehensive income associated with assets held for sale		5,813		1,725
Equity attributable to owners of the parent		947,894		965,753
Non-controlling interests		204,873		198,613
Total equity		1,152,767		1,164,366
Total liabilities and equity	¥	3,739,477	¥	3,934,818

## (2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income

### Consolidated Statement of Income

Third Quarter ended December 31, 2024 and 2023

Millions of yen	Q3 FY2024		Q3 FY2023	
Sales revenue	¥	1,904,833	¥	1,806,869
Cost of sales		(1,367,051)		(1,393,745)
Gross profit		537,782		413,124
Selling, general and administrative expenses		(446,357)		(519,459)
Other operating income		45,701		15,519
Other operating expenses		(24,336)		(29,541)
Share of profit (loss) of investments accounted for using the equity method		32,644		(40,277)
Operating income (loss)		145,434		(160,634)
Finance income		34,757		34,537
Finance expenses		(140,120)		(33,856)
Income (loss) before taxes		40,071		(159,953)
Income tax expenses		623		(4,993)
Net income (loss)		40,694		(164,946)
Net income (loss) attributable to:				
Owners of the parent		28,581		(109,778)
Non-controlling interests		12,113		(55,168)
Net income (loss)	¥	40,694	¥	(164,946)

Yen	Q3 FY2024		Q3 FY2023	
Earnings per share:				
Basic earnings (loss) per share		17.47		(67.13)
Diluted earnings per share		17.47		—

## Consolidated Statement of Comprehensive Income

Third Quarter ended December 31, 2024 and 2023

Millions of yen	Q3 FY2024	Q3 FY2023
Net income (loss)	¥ 40,694	¥ (164,946)
Other comprehensive income:		
Items that will not be reclassified to profit or loss		
Remeasurements of financial assets (equity instruments) measured at fair value through other comprehensive income	(22,306)	48,082
Remeasurements of defined benefit plans	(136)	8,996
Share of other comprehensive income of investments accounted for using the equity method	1,942	1,412
Total items that will not be reclassified to profit or loss	(20,500)	58,490
Items that may be subsequently reclassified to profit or loss		
Remeasurements of financial assets (debt instruments) measured at fair value through other comprehensive income	(52)	—
Cash flow hedge	(254)	851
Exchange differences on conversion of foreign operations	(12,511)	71,566
Share of other comprehensive income of investments accounted for using the equity method	(6,400)	20,981
Total items that may be subsequently reclassified to profit or loss	(19,217)	93,398
Other comprehensive income, net of taxes	(39,717)	151,888
Total comprehensive income	977	(13,058)
Total comprehensive income attributable to:		
Owners of the parent	(7,972)	10,526
Non-controlling interests	8,949	(23,584)
Total comprehensive income	¥ 977	¥ (13,058)

### (3) Consolidated Statement of Changes in Equity

Third Quarter ended December 31, 2024

Millions of yen	Equity attributable to owners of the parent						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity		
					Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans	
Balance as of April 1, 2024	¥ 89,938	¥ 237	¥ 578,175	¥ (8,355)	¥ 83,448	¥ —	
Net income (loss)	—	—	28,581	—	—	—	
Other comprehensive income	—	—	—	—	(16,205)	138	
<b>Total comprehensive income</b>	—	—	28,581	—	(16,205)	138	
Issuance of new shares	120	120	—	—	—	—	
Purchase of treasury shares	—	—	—	(4)	—	—	
Disposal of treasury shares	—	(0)	—	0	—	—	
Dividends	—	—	(9,818)	—	—	—	
Changes resulting from additions to consolidation	—	—	—	—	—	—	
Changes resulting from loss of control of subsidiaries	—	—	—	—	—	—	
Changes in interest due to transactions with non-controlling interests	—	(306)	—	—	—	—	
Transfer from other components of equity to retained earnings	—	—	38,345	—	(38,207)	(138)	
Others, net	—	—	—	—	—	—	
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—	(98)	—	
<b>Total transactions with owners</b>	120	(186)	28,527	(4)	(38,305)	(138)	
<b>Balance as of December 31, 2024</b>	<b>¥ 90,059</b>	<b>¥ 51</b>	<b>¥ 635,283</b>	<b>¥ (8,359)</b>	<b>¥ 28,938</b>	<b>¥ —</b>	

	Equity attributable to owners of the parent							Non-controlling interests	Total equity
	Other components of equity			Other comprehensive income associated with assets held for sale	Equity attributable to owners of the parent				
	Cash flow hedges	Exchange differences on conversion of foreign operations	Total						
Balance as of April 1, 2024	¥ 319	¥ 220,266	¥ 304,033	¥ 1,725	¥ 965,753	¥ 198,613	¥ 1,164,366		
Net income (loss)	—	—	—	—	28,581	12,113	40,694		
Other comprehensive income	(239)	(18,372)	(34,678)	(1,875)	(36,553)	(3,164)	(39,717)		
<b>Total comprehensive income</b>	<b>(239)</b>	<b>(18,372)</b>	<b>(34,678)</b>	<b>(1,875)</b>	<b>(7,972)</b>	<b>8,949</b>	<b>977</b>		
Issuance of new shares	—	—	—	—	240	—	240		
Purchase of treasury shares	—	—	—	—	(4)	—	(4)		
Disposal of treasury shares	—	—	—	—	0	—	0		
Dividends	—	—	—	—	(9,818)	(3,023)	(12,841)		
Changes resulting from additions to consolidation	—	—	—	—	—	—	—		
Changes resulting from loss of control of subsidiaries	—	—	—	—	—	28	28		
Changes in interest due to transactions with non-controlling interests	—	—	—	—	(306)	306	—		
Transfer from other components of equity to retained earnings	—	—	(38,345)	—	—	—	—		
Others, net	—	—	—	—	—	—	—		
Transfer to other comprehensive income associated with assets held for sale	—	(5,865)	(5,963)	5,963	—	—	—		
<b>Total transactions with owners</b>	<b>—</b>	<b>(5,865)</b>	<b>(44,308)</b>	<b>5,963</b>	<b>(9,888)</b>	<b>(2,689)</b>	<b>(12,577)</b>		
<b>Balance as of December 31, 2024</b>	<b>¥ 80</b>	<b>¥ 196,029</b>	<b>¥ 225,047</b>	<b>¥ 5,813</b>	<b>¥ 947,894</b>	<b>¥ 204,873</b>	<b>¥ 1,152,767</b>		

Third Quarter ended December 31, 2023

	Equity attributable to owners of the parent						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity		
					Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans	
Millions of yen							
Balance as of April 1, 2023	¥ 89,810	¥ —	¥ 891,552	¥ (8,349)	¥ 81,869	¥ —	
Net income (loss)	—	—	(109,778)	—	—	—	
Other comprehensive income	—	—	—	—	30,631	8,997	
Total comprehensive income	—	—	(109,778)	—	30,631	8,997	
Issuance of new shares	128	128	—	—	—	—	
Purchase of treasury shares	—	—	—	(4)	—	—	
Disposal of treasury shares	—	0	—	0	—	—	
Dividends	—	—	(19,628)	—	—	—	
Changes resulting from additions to consolidation	—	—	—	—	—	—	
Changes resulting from loss of control of subsidiaries	—	—	349	—	—	—	
Changes in interest due to transactions with non-controlling interests	—	—	—	—	—	—	
Transfer from other components of equity to retained earnings	—	—	30,597	—	(21,600)	(8,997)	
Others, net	—	—	(74)	—	—	—	
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—	—	—	
Total transactions with owners	128	128	11,244	(4)	(21,600)	(8,997)	
Balance as of December 31, 2023	¥ 89,938	¥ 128	¥ 793,018	¥ (8,353)	¥ 90,900	¥ —	

	Equity attributable to owners of the parent						
	Other components of equity			Other comprehensive income associated with assets held for sale	Equity attributable to owners of the parent	Non-controlling interests	Total equity
	Cash flow hedges	Exchange differences on conversion of foreign operations	Total				
Balance as of April 1, 2023	¥ (539)	¥ 116,500	¥ 197,830	¥ 349	¥ 1,171,192	¥ 317,997	¥ 1,489,189
Net income (loss)	—	—	—	—	(109,778)	(55,168)	(164,946)
Other comprehensive income	873	79,803	120,304	—	120,304	31,584	151,888
Total comprehensive income	873	79,803	120,304	—	10,526	(23,584)	(13,058)
Issuance of new shares	—	—	—	—	256	—	256
Purchase of treasury shares	—	—	—	—	(4)	—	(4)
Disposal of treasury shares	—	—	—	—	0	—	0
Dividends	—	—	—	—	(19,628)	(4,488)	(24,116)
Changes resulting from additions to consolidation	—	—	—	—	—	55	55
Changes resulting from loss of control of subsidiaries	—	—	—	(349)	—	—	—
Changes in interest due to transactions with non-controlling interests	—	—	—	—	—	7	7
Transfer from other components of equity to retained earnings	—	—	(30,597)	—	—	—	—
Others, net	—	—	—	—	(74)	—	(74)
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—	—	—	—
Total transactions with owners	—	—	(30,597)	(349)	(19,450)	(4,426)	(23,876)
Balance as of December 31, 2023	¥ 334	¥ 196,303	¥ 287,537	¥ —	¥ 1,162,268	¥ 289,987	¥ 1,452,255

#### (4) Consolidated Statement of Cash Flows

Third Quarter ended December 31, 2024 and 2023

Millions of yen	Q3 FY2024	Q3 FY2023
Cash flows from operating activities:		
Income (loss) before taxes	¥ 40,071	¥ (159,953)
Depreciation and amortization	99,431	117,433
Impairment losses	5,510	15,441
Share of (profit) loss of investments accounted for using the equity method	(32,644)	40,277
Interest and dividend income	(13,086)	(16,792)
Interest expenses	22,479	21,661
Restructuring costs	14,824	25,630
(Gain) loss on sale of property, plant and equipment, and intangible assets	(11,469)	(1,146)
(Increase) decrease in trade receivables	31,719	65,924
(Increase) decrease in inventories	(8,165)	15,300
Increase (decrease) in trade payables	1,879	(19,921)
Increase (decrease) in unearned revenue	(18,248)	(11,223)
Increase (decrease) in provisions	5,883	(50,365)
Others, net	34,167	(110,233)
Subtotal	172,351	(67,967)
Interest and dividends received	17,724	22,393
Interest paid	(22,533)	(20,958)
Income taxes refund (paid)	(5,482)	(41,931)
Restructuring costs paid	(21,320)	(26,501)
Net cash provided by (used in) operating activities	140,740	(134,964)
Cash flows from investing activities:		
Net (increase) decrease in securities	1,446	(5,789)
Purchase of property, plant and equipment, and intangible assets	(106,203)	(116,136)
Proceeds from sales of property, plant and equipment, and intangible assets	14,743	1,769
Proceeds from sales of subsidiaries	4,053	11,074
Payments for sales of subsidiaries	(3,000)	—
Purchase of other financial assets	(3,621)	(3,782)
Proceeds from sales and redemption of other financial assets	153,967	64,418
Increase in loan receivables	(90)	(26,011)
Others, net	(4,572)	(3,350)
Net cash provided by (used in) investing activities	56,723	(77,807)
Cash flows from financing activities:		
Net increase (decrease) in short-term borrowings	(34,443)	121,145
Net increase (decrease) in commercial paper	42,000	53,000
Proceeds from long-term borrowings	146	31,073
Repayments of long-term borrowings	(101,589)	(16,274)
Proceeds from issuance of bonds	99,161	39,836
Redemption of bonds	(120,000)	(30,000)
Repayments of finance lease liabilities	(14,257)	(13,281)
Cash dividends paid	(9,852)	(19,640)
Cash dividends paid to non-controlling interests	(3,025)	(4,498)
Others, net	177	(257)
Net cash provided by (used in) financing activities	(141,682)	161,104
Effect of exchange rate changes on cash and cash equivalents	(2,536)	20,840
Increase (decrease) in cash and cash equivalents	53,245	(30,827)
Cash and cash equivalents at the beginning of the year	217,449	305,844
Net increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale	(12,393)	1,135
Cash and cash equivalents at the end of the period	¥ 258,301	¥ 276,152

## **(5) Notes to Consolidated Financial Statements**

### **Framework of Financial Report**

The Group's quarterly consolidated financial statements are prepared in accordance with Article 5, Paragraph 2 of the Tokyo Stock Exchange, Inc.'s Standards for the Preparation of Quarterly Financial Statements, applying the omitted disclosures as set forth in Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements.

### **Going Concern Assumption**

Not applicable.

### **Changes in Accounting Estimates**

The Company classifies the loans and long-term accrued interest receivable to Petro Rabigh as financial assets measured at fair value through profit or loss (FVTPL) and Level 3 in the fair value hierarchy. The fair value is calculated using the discounted cash flow method.

As announced on August 7, 2024, the Company and Saudi Arabian Oil Company have agreed to waive existing revolving shareholder loans of US\$750 million each.

Based on this agreement, the Company derecognized the financial assets for the US\$500 million waived in August, 2024. Additionally, for the US\$250 million that was waived in January 2025, the estimated future cash flows have been remeasured, resulting in a fair value of zero in Q3 FY2024. Consequently, the Company recognized a loss of ¥109,791 million as finance expenses due to the waiver of loans and long-term accrued interest receivable in Q3 FY2024.

## Segment Information

### 1. Reportable Segments

The reportable segments of the Group refer to business units for which separate financial information is available and that are reviewed regularly at the Board of Directors meeting in order to determine the allocation of management resources and evaluate the business performance of each business unit.

The Group divides its operations into business sectors identified by products and services, which manage manufacturing, sales, and research in an integrated manner. Each business sector is responsible for developing comprehensive domestic and overseas strategies with respect to its products and services, and operates its business activities.

The Group is advancing fundamental structural reforms and committed to its high growth strategy, in which it aims to contribute to solving social issues by leveraging innovative technologies and to continue to be a company with global presence. As part of the structural reforms, the Group implemented reorganization on October 1, 2024, establishing four new business sectors. Accordingly, effective Q3 FY2024, the Group changed its reportable segments from the five segments of "Essential Chemicals & Plastics," "Energy & Functional Materials," "IT-related Chemicals," "Health & Crop Sciences," and "Pharmaceuticals" into the five segments of "Agro & Life Solutions," "ICT & Mobility Solutions," "Advanced Medical Solutions," "Essential & Green Materials," and "Sumitomo Pharma."

The segment information for Q3 FY2023 has been reclassified to reflect the change of the reportable segments.

The major products and services of each reportable segment are as follows:

Reportable Segment	Major Products and Services
Agro & Life Solutions	Crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, feed additives, etc.
ICT & Mobility Solutions	Optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, high-purity aluminum and alumina, specialty chemicals, additives, engineering plastics, battery materials, etc.
Advanced Medical Solutions	Contract development and manufacturing organization business for small-molecule active ingredients and intermediates, oligonucleic acid drug substances, and regenerative medicine and cell therapy products, etc.
Essential & Green Materials	Synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, synthetic resin processed products, industrial aluminum and alumina, synthetic rubber, etc.
Sumitomo Pharma	Small molecule pharmaceuticals

### 2. Reportable Segment Information

The accounting methods for each reportable segment are, in principle, identical to those used in the consolidated financial statements. The segment profit or loss is core operating income, which is calculated from operating income after excluding effects from non-recurring factors.

Inter-segment sales revenue is based on market prices.

### Third Quarter Fiscal Year 2024

Millions of yen	Agro & Life Solutions	ICT & Mobility Solutions	Advanced Medical Solutions	Essential & Green Materials	Sumitomo Pharma	Total	Others (Note 1)	Adjustments (Note 2)	Consolidated
Sales revenue:									
Sales revenues from external customers	¥ 363,076	¥ 461,216	¥ 40,728	¥ 672,915	¥ 292,815	¥ 1,830,750	¥ 74,083	¥ —	¥ 1,904,833
Inter-segment sales revenues	1,214	2,607	6,854	4,059	66	14,800	49,594	(64,394)	—
<b>Total sales revenue</b>	<b>364,290</b>	<b>463,823</b>	<b>47,582</b>	<b>676,974</b>	<b>292,881</b>	<b>1,845,550</b>	<b>123,677</b>	<b>(64,394)</b>	<b>1,904,833</b>
Segment profit (loss) : core operating income (loss)	¥ 19,517	¥ 59,720	¥ 1,203	¥ (44,340)	¥ 19,858	¥ 55,958	¥ 23,752	¥ (19,645)	¥ 60,065

Note 1: "Others" represents businesses such as radiopharmaceuticals, supplying electrical power and steam, providing services for the design, engineering, and construction management of chemical plants, and providing transport and warehousing, which are not included in reportable segments.

Note 2: ¥(19,645) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥392 million and corporate expenses of ¥(20,037) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not treated as attributable to specific reportable segments.

### Third Quarter Fiscal Year 2023

Millions of yen	Agro & Life Solutions	ICT & Mobility Solutions	Advanced Medical Solutions	Essential & Green Materials	Sumitomo Pharma	Total	Others (Note 1)	Adjustments (Note 2)	Consolidated
Sales revenue:									
Sales revenues from external customers	¥ 347,185	¥ 441,285	¥ 38,202	¥ 681,705	¥ 234,739	¥ 1,743,116	¥ 63,753	¥ —	¥ 1,806,869
Inter-segment sales revenues	1,621	2,359	8,629	3,904	34	16,547	56,607	(73,154)	—
<b>Total sales revenue</b>	<b>348,806</b>	<b>443,644</b>	<b>46,831</b>	<b>685,609</b>	<b>234,773</b>	<b>1,759,663</b>	<b>120,360</b>	<b>(73,154)</b>	<b>1,806,869</b>
Segment profit (loss) : core operating income (loss)	¥ (2,902)	¥ 43,954	¥ 2,999	¥ (60,538)	¥ (96,364)	¥ (112,851)	¥ 12,106	¥ (13,121)	¥ (113,866)

Note 1: "Others" represents businesses such as radiopharmaceuticals, supplying electrical power and steam, providing services for the design, engineering, and construction management of chemical plants, and providing transport and warehousing, which are not included in reportable segments.

Note 2: ¥(13,121) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥1,470 million and corporate expenses of ¥(14,591) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not treated as attributable to specific reportable segments.

Adjustments to income (loss) before taxes from core operating income (loss) were as follows:

Millions of yen	Q3 FY2024	Q3 FY2023
Core operating income (loss)	¥ 60,065	¥ (113,866)
Share of profit (loss) of investments accounted for using the equity method (non-recurring factors)	85,987	(5,060)
Gains on sales of property, plant and equipment, and intangible assets	11,469	1,146
Gains on fair value measurement of the residual interest	9,449	—
Changes in fair value of contingent consideration	1,038	(118)
Restructuring costs	(14,824)	(25,630)
Impairment losses	(5,510)	(15,441)
Others, net	(2,240)	(1,665)
Operating income (loss)	145,434	(160,634)
Finance income	34,757	34,537
Finance expenses	(140,120)	(33,856)
Income (loss) before taxes	¥ 40,071	¥ (159,953)

Note: Breakdown of share of profit (loss) of investments accounted for using the equity method included in operating income was as follows:

Millions of yen	Q3 FY2024	Q3 FY2023
Share of profit (loss) of investments accounted for using the equity method	¥ 32,644	¥ (40,277)
Of which resulting from recurring factors	(53,343)	(35,217)
Of which resulting from non-recurring factors	85,987	(5,060)